A comprehensive review and update on the non-biologic treatment of adult noninfectious uveitis: part I

Bibliography

• Vadot E. Epidemiology of intermediate uveitis: a prospective study in Savoy. Dev Ophthalmol 1992;23:33-4
   PubMedGoogle Scholar
• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica 2004;218(4):223-36
   PubMed Web of Science ®Google Scholar
• de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res 2011;30(6):452-70
   PubMed Web of Science ®Google Scholar
• Anglade E, Whitcup SM. The diagnosis and management of uveitis. Drugs 1995;49(2):213-23
   PubMedGoogle Scholar
• Haupert CL, Jaffe GJ. New and emerging treatments for patients with uveitis. Int Ophthalmol Clin 2000;40(2):205-20
   PubMedGoogle Scholar
• Brumm MV, Nguyen QD. Fluocinolone acetonide intravitreal sustained release device–a new addition to the armamentarium of uveitic management. Int J Nanomedicine 2007;2(1):55-64
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000;41(11):3569-75
   PubMed Web of Science ®Google Scholar
• Lim LL, Smith JR, Rosenbaum JT. Retisert (Bausch & Lomb/Control Delivery Systems). Curr Opin Investig Drugs 2005;6(11):1159-67
   PubMedGoogle Scholar
• Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006;113(6):1020-7
   PubMed Web of Science ®Google Scholar
• Multicenter Uveitis Steroid Treatment Trial Research Group. Kempen JH, Altaweel MM, Holbrook JT, et al. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149(4):550-61; e10
   PubMed Web of Science ®Google Scholar
• Khalifa Y, Loh AR, Acharya NR. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm 2009;17(6):431-3
   PubMed Web of Science ®Google Scholar
• Mahajan VB, Gehrs KM, Goldstein DA, et al. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology 2009;116(3):552-7; e1
   PubMed Web of Science ®Google Scholar
• Patel CC, Mandava N, Oliver SC, et al. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Retina 2012;32(3):537-42
   PubMed Web of Science ®Google Scholar
• Park UC, Kim SJ, Yu HG. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behcet uveitis. Ocul Immunol Inflamm 2011;19(4):282-3
   PubMed Web of Science ®Google Scholar
• Rofagha S, Prechanond T, Stewart JM. Late spontaneous dissociation of a fluocinolone acetonide implant (Retisert). Ocul Immunol Inflamm 2013;21(1):77-8
   PubMed Web of Science ®Google Scholar
• Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52(1):80-6
   PubMed Web of Science ®Google Scholar
• London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther 2011;28(5):351-66
   PubMed Web of Science ®Google Scholar
• Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother 2011;12(7):1127-31
   PubMed Web of Science ®Google Scholar
• Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129(5):545-53
   PubMed Web of Science ®Google Scholar
• Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118(12):2453-60
   PubMed Web of Science ®Google Scholar
• Williams GA, Haller JA, Kuppermann BD, et al. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol 2009;147(6):1048-54; 54 e1-2
   PubMed Web of Science ®Google Scholar
• Dutra Medeiros M, Postorino M, Navarro R, et al. Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 2014;231(3):141-6
   PubMed Web of Science ®Google Scholar
• Saatci AO, Doruk HC, Yaman A. Intravitreal dexamethasone implant (ozurdex) in coats’ disease. Case Rep Ophthalmol 2013;4(3):122-8
   PubMedGoogle Scholar
• Arcinue CA, Ceron OM, Foster CS. A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis. J Ocul Pharmacol Ther 2013;29(5):501-7
   PubMed Web of Science ®Google Scholar
• Khurana RN, Appa SN, McCannel CA, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology 2014;121(1):67-71
   PubMed Web of Science ®Google Scholar
• Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov Today 2008;13(3-4):135-43
   PubMed Web of Science ®Google Scholar
• Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv 2008;5(9):1039-46
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Hafiz G, Shah SM, et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert. Ophthalmology 2010;117(7):1393-9; e3
   PubMed Web of Science ®Google Scholar
• Sanford M. Fluocinolone acetonide intravitreal implant (Iluvien(R)): in diabetic macular oedema. Drugs 2013;73(2):187-93
   PubMedGoogle Scholar
• Schwartz SG, Flynn HW Jr. Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011;12(3):347-51
   PubMed Web of Science ®Google Scholar
• Kothari HV, Lee WH, Ku EC. An alternate mechanism for regulation of leukotriene production in leukocytes: studies with an anti-inflammatory drug, sodium diclofenac. Biochim Biophys Acta 1987;921(3):502-11
   PubMed Web of Science ®Google Scholar
• Costagliola C, Parmeggiani F, Antinozzi PP, et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp Eye Res 2005;81(5):610-15
   PubMed Web of Science ®Google Scholar
• Leske MC, Chylack LT Jr, Wu SY. The Lens Opacities Case-Control Study. Risk factors for cataract. Arch Ophthalmol 1991;109(2):244-51
   PubMedGoogle Scholar
• Rabiah PK, Fiscella RG, Tessler HH. Intraocular penetration of periocular ketorolac and efficacy in experimental uveitis. Invest Ophthalmol Vis Sci 1996;37(4):613-18
   PubMedGoogle Scholar
• Kim SJ, Adams NA, Toma HS, et al. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 2008;28(4):595-605
   PubMedGoogle Scholar
• Soheilian M, Karimi S, Ramezani A, Peyman GA. Pilot study of intravitreal injection of diclofenac for treatment of macular edema of various etiologies. Retina 2010;30(3):509-15
   PubMed Web of Science ®Google Scholar
• Ramezani A, Fard Esmaeilpour N, Eskandari A, et al. Intravitreal diclofenac for refractory uveitic cystoid macular edema. J Ophthalmic Vis Res 2013;8(1):47-52
   PubMedGoogle Scholar
• Baranano DE, Kim SJ, Edelhauser HF, et al. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br J Ophthalmol 2009;93(10):1387-90
   PubMed Web of Science ®Google Scholar
• Durairaj C, Shah JC, Senapati S, Kompella UB. Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR). Pharm Res 2009;26(5):1236-60
   PubMed Web of Science ®Google Scholar
• Durairaj C, Kim SJ, Edelhauser HF, et al. Influence of dosage form on the intravitreal pharmacokinetics of diclofenac. Invest Ophthalmol Vis Sci 2009;50(10):4887-97
   PubMed Web of Science ®Google Scholar
• Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2000;130(4):492-513
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. Bmj 2009;339:b2480
   PubMedGoogle Scholar
• Gallego-Pinazo R, Dolz-Marco R, Martinez-Castillo S, et al. Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis. Inflamm Allergy Drug Targets 2013;12(1):38-45
   PubMedGoogle Scholar
• Weinblatt ME, Kremer JM. Methotrexate in rheumatoid arthritis. J Am Acad Dermatol 1988;19(1 Pt 1):126-8
   PubMedGoogle Scholar
• Foster CS. Pharmacologic treatment of immune disorders. In: Albert DM, Jakobiec FA, editor. Albert and jakobiec's principles and practice of ophthalmology, WB Saunders, New York, NY; 1994. p. 1076-84
   Google Scholar
• Association AM. AMA drug evaluations. 1991. p. 396; 1059, 654-5, 671-2, 843-4, 972-3, 891-913, 2009-[140-1, 351-3
   Google Scholar
• Lally EV, Ho G Jr. A review of methotrexate therapy in Reiter syndrome. Semin Arthritis Rheum 1985;15(2):139-45
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009;116(11):2188-98; e1
   PubMed Web of Science ®Google Scholar
• Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. Rheumatology 2013;52(5):825-31
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2005;32(2):362-5
   PubMed Web of Science ®Google Scholar
• Rothova A, Ossewaarde-van Norel A, Los LI, Berendschot TT. Efficacy of low-dose methotrexate treatment in birdshot chorioretinopathy. Retina 2011;31(6):1150-5
   PubMedGoogle Scholar
• Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116(4):797-801
   PubMed Web of Science ®Google Scholar
• Hardwig PW, Pulido JS, Erie JC, et al. Intraocular methotrexate in ocular diseases other than primary central nervous system lymphoma. Am J Ophthalmol 2006;142(5):883-5
   PubMedGoogle Scholar
• Ridley MG, Wolfe CS, Mathews JA. Life threatening acute pneumonitis during low dose methotrexate treatment for rheumatoid arthritis: a case report and review of the literature. Ann Rheum Dis 1988;47(9):784-8
   PubMedGoogle Scholar
• Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med 1975;82(1):84-95
   PubMedGoogle Scholar
• Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991;25(2 Pt 1):306-18
   PubMedGoogle Scholar
• Callen JP, Kulp-Shorten C. Methotrexate. WB Saunders, Philadelphia; 1991
   Google Scholar
• Lipsky JJ. Mycophenolate mofetil. Lancet 1996;348(9038):1357-9
   PubMed Web of Science ®Google Scholar
• Moudgil A, Bagga A, Jordan SC. Mycophenolate mofetil therapy in frequently relapsing steroid-dependent and steroid-resistant nephrotic syndrome of childhood: current status and future directions. Pediatr Nephrol 2005;20(10):1376-81
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47(2-3):85-118
   PubMed Web of Science ®Google Scholar
• Thorne JE, Jabs DA, Qazi FA, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology 2005;112(8):1472-7
   PubMed Web of Science ®Google Scholar
• Teoh SC, Hogan AC, Dick AD, Lee RW. Mycophenolate mofetil for the treatment of uveitis. Am J Ophthalmol 2008;146(5):752-60; 60 e1-3
   PubMedGoogle Scholar
• Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008;115(10):1826-32
   PubMed Web of Science ®Google Scholar
• Kempen JH, Gangaputra S, Daniel E, et al. Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence. Am J Ophthalmol 2008;146(6):802-12; e1
   PubMed Web of Science ®Google Scholar
• Kingdon EJ, McLean AG, Psimenou E, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10(9):606-11
   PubMedGoogle Scholar
• Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60(3):225-32
   PubMed Web of Science ®Google Scholar
• Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995;345(8961):1321-5
   PubMed Web of Science ®Google Scholar
• A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996;61(7):1029-37
   PubMed Web of Science ®Google Scholar
• Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization. Pediatr Transplant 2004;8(5):445-53
   PubMedGoogle Scholar
• Dipchand AI, Benson L, McCrindle BW, et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant 2001;5(2):112-18
   PubMed Web of Science ®Google Scholar
• van Mourik ID, Kelly DA. Immunosuppressive drugs in paediatric liver transplantation. Paediatr Drugs 2001;3(1):43-60
   PubMedGoogle Scholar
• Filler G, Hansen M, LeBlanc C, et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003;18(5):445-9
   PubMed Web of Science ®Google Scholar
• Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005;129(4):534-8
   PubMed Web of Science ®Google Scholar
• Novak I, Frank R, Vento S, et al. Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 2005;20(9):1265-8
   PubMedGoogle Scholar
• Greiner K, Varikkara M, Santiago C, Forrester JV. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis]. Ophthalmologe 2002;99(9):691-4
   PubMedGoogle Scholar
• Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 2003;110(5):1061-5
   PubMed Web of Science ®Google Scholar
• Siepmann K, Huber M, Stubiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol 2006;244(7):788-94
   PubMed Web of Science ®Google Scholar
• Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol 2010;149(3):423-32; e1-2
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 1998;352(9121):35-6
   PubMed Web of Science ®Google Scholar
• Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 1999;106(2):370-4
   PubMedGoogle Scholar
• Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Experiment Ophthalmol 2003;31(6):487-91
   PubMedGoogle Scholar
• Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol 2007;91(2):180-4
   PubMedGoogle Scholar
• Chang PY, Giuliari GP, Shaikh M, et al. Mycophenolate mofetil monotherapy in the management of paediatric uveitis. Eye (Lond) 2011;25(4):427-35
   PubMed Web of Science ®Google Scholar
• Cervantes-Castaneda RA, Gonzalez-Gonzalez LA, Cordero-Coma M, et al. Combined therapy of cyclosporine A and mycophenolate mofetil for the treatment of birdshot retinochoroidopathy: a 12-month follow-up. Br J Ophthalmol 2013;97(5):637-43
   PubMedGoogle Scholar
• Doycheva D, Zierhut M, Blumenstock G, et al. Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2011;249(8):1235-43
   PubMed Web of Science ®Google Scholar
• Okada AA. Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13(5):335-51
   PubMed Web of Science ®Google Scholar
• Neff RT, Hurst FP, Falta EM, et al. Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation. Transplantation 2008;86(10):1474-8
   PubMed Web of Science ®Google Scholar
• Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 2004;43(1):13-18
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 2001;131(5):679
   PubMed Web of Science ®Google Scholar
• Arcinue CA, Radwan A, Lebanan MO, Foster CS. Comparison of two different combination immunosuppressive therapies in the treatment of Vogt-Koyonagi-Harada syndrome. Ocul Immunol Inflamm 2013;21(1):47-52
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Shams H, et al. Combination of pulse cyclophosphamide and azathioprine in ocular manifestations of Behcet’s disease: longitudinal study of up to 10 years. Int J Rheum Dis 2014;17(4):444-52
   PubMed Web of Science ®Google Scholar
• Pilly B, Heath G, Tschuor P, et al. Overview and recent developments in the medical management of paediatric uveitis. Expert Opin Pharmacother 2013;14(13):1787-95
   PubMed Web of Science ®Google Scholar
• Dorr RT, Fritz WL. Cancer chemotherapy handbook. Elsevier/North Holland, New York; 1980
   Google Scholar
• Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012;2(1):21-8
   PubMedGoogle Scholar
• Borel JF, Feurer C, Magnee C, Stahelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 1977;32(6):1017-25
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Rook AH, et al. Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 1983;2(8344):235-8
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC. Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol 1985;1(4):369-82
   PubMedGoogle Scholar
• Kacmaz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010;117(3):576-84
   PubMed Web of Science ®Google Scholar
• Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo) 1975;28(10):727-32
   PubMed Web of Science ®Google Scholar
• Kahan BD. Sirolimus: a comprehensive review. Expert Opin Pharmacother 2001;2(11):1903-17
   PubMedGoogle Scholar
• Napoli KL, Taylor PJ. From beach to bedside: history of the development of sirolimus. Ther Drug Monit 2001;23(5):559-86
   PubMed Web of Science ®Google Scholar
• Roberge FG, Kozhich A, Chan CC, et al. Inhibition of cellular transfer of experimental autoimmune uveoretinitis by Rapamycin. Ocul Immunol Inflamm 1993;1(3):269-73
   PubMedGoogle Scholar
• Mudumba S, Bezwada P, Takanaga H, et al. Tolerability and pharmacokinetics of intravitreal sirolimus. J Ocul Pharmacol Ther 2012;28(5):507-14
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect 2013;3(1):32
   PubMedGoogle Scholar
• Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo) 1987;40(9):1249-55
   PubMed Web of Science ®Google Scholar
• Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol 1994;118(6):723-9
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114(5):1000-6
   PubMed Web of Science ®Google Scholar
• Lee RW, Greenwood R, Taylor H, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology 2012;119(6):1223-30
   PubMed Web of Science ®Google Scholar
• Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005;123(5):634-41
   PubMedGoogle Scholar
• Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64(1):36-42
   PubMed Web of Science ®Google Scholar
• Hennig M, Bauer D, Wasmuth S, et al. Everolimus improves experimental autoimmune uveoretinitis. Exp Eye Res 2012;105:43-52
   PubMed Web of Science ®Google Scholar
• Heiligenhaus A, Zurek-Imhoff B, Roesel M, et al. Everolimus for the treatment of uveitis refractory to cyclosporine A: a pilot study. Graefes Arch Clin Exp Ophthalmol 2013;251(1):143-52
   PubMedGoogle Scholar
• Makinodan T, Santos GW, Quinn RP. Immunosuppressive drugs. Pharmacol Rev 1970;22(2):189-247
   PubMedGoogle Scholar
• Fauci AS, Wolff SM, Johnson JS. Effect of cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med 1971;285(27):1493-6
   PubMedGoogle Scholar
• de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150(10):670-80
   PubMed Web of Science ®Google Scholar
• Ramos PC, Mendez MJ, Ames PR, et al. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996;14(3):295-9
   PubMedGoogle Scholar
• Roda Perez E. [Case of uveitis of unknown etiology treated with nitrogen mustards]. Rev Clin Esp 1951;41(4):265-7
   PubMedGoogle Scholar
• Durrani K, Papaliodis GN, Foster CS. Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety. Ophthalmology 2004;111(5):960-5
   PubMedGoogle Scholar
• Akpek EK, Jabs DA, Tessler HH, et al. Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 2002;109(8):1506-13
   PubMedGoogle Scholar
• Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet’s syndrome: a single masked trial. Br J Ophthalmol 1992;76(4):241-3
   PubMed Web of Science ®Google Scholar
• Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B. Long-term effects of cyclophosphamide and colchicine treatment in Behcet’s disease. Ann Ophthalmol 1991;23(4):148-51
   PubMedGoogle Scholar
• Ando K, Fujino Y, Hijikata K, et al. Epidemiological features and visual prognosis of Behcet’s disease. Jpn J Ophthalmol 1999;43(4):312-17
   PubMedGoogle Scholar
• Suelves AM, Arcinue CA, Gonzalez-Martin JM, et al. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease. Ophthalmology 2013;120(6):1201-9
   PubMed Web of Science ®Google Scholar
• Khan IJ, Barry RJ, Amissah-Arthur KN, et al. Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease. Br J Ophthalmol 2013;97(9):1118-22
   PubMedGoogle Scholar
• Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996;39(9):1475-82
   PubMed Web of Science ®Google Scholar
• Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98(1):76-85
   PubMed Web of Science ®Google Scholar
• Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997;90(6):401-9
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Treatment of severe refractory uveitis with intravenous cyclophosphamide. J Rheumatol 1994;21(1):123-5
   PubMed Web of Science ®Google Scholar
• Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener’s granulomatosis. Arthritis Rheum 1997;40(12):2187-98
   PubMedGoogle Scholar
• Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 1982;89(4):340-53
   PubMedGoogle Scholar
• Biswas J, Rao NA. Management of intraocular inflammation. Mosby, St. Louis; 1994
   Google Scholar
• Foster CS. Nonsteroidal anti-inflammatory and immunossupressive agents. In: Lamberts DW, Potter DE, editors. Clinical ophthalmic pharmacology. Little Brown, Boston; 1987
   Google Scholar
• Gery I, Nussenblatt R. Immunosuppressive drugs. In: Sears ML, editor. Pharmacology of the eye. Springer-Verlag, Berlin; 1984
   Google Scholar
• Mamo JG, Azzam SA. Treatment of Behcet’s disease with chlorambucil. Arch Ophthalmol 1970;84(4):446-50
   PubMed Web of Science ®Google Scholar
• Benezra D, Cohen E. Treatment and visual prognosis in Behcet’s disease. Br J Ophthalmol 1986;70(8):589-92
   PubMed Web of Science ®Google Scholar
• Bietti GB, Cerulli L, Pivetti-Pezzi P. Behcet’s disease and immunosuppressive treatment. Our personal experience. Mod Probl Ophthalmol 1976;16:314-23
   PubMedGoogle Scholar
• O’Duffy JD, Robertson DM, Goldstein NP. Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet’s disease. Am J Med 1984;76(1):75-84
   PubMed Web of Science ®Google Scholar
• Pivetti Pezzi P, Gasparri V, De Liso P, Catarinelli G. Prognosis in Behcet’s disease. Ann Ophthalmol 1985;17(1):20-5
   PubMedGoogle Scholar
• Tricoulis D. Treatment of Behcet’s disease with chlorambucil. Br J Ophthalmol 1976;60(1):55-7
   PubMed Web of Science ®Google Scholar
• Abdalla MI, el-D Bahoat N. Long-lasting remission of Behcet’s disease after chlorambucil therapy. Br J Ophthalmol 1973;57(9):706-11
   PubMed Web of Science ®Google Scholar
• Elliott JH, Ballinger WH. Behcet’s syndrome: treatment with chlorambucil. Trans Am Ophthalmol Soc 1984;82:264-81
   PubMedGoogle Scholar
• Godfrey WA, Epstein WV, O’Connor GR, et al. The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol 1974;78(3):415-28
   PubMed Web of Science ®Google Scholar
• Andrasch RH, Pirofsky B, Burns RP. Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 1978;96(2):247-51
   PubMed Web of Science ®Google Scholar
• Jennings T, Tessler HH. Twenty cases of sympathetic ophthalmia. Br J Ophthalmol 1989;73(2):140-5
   PubMed Web of Science ®Google Scholar
• Kanski JJ. Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol 1977;95(10):1794-7
   PubMedGoogle Scholar
• Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. Ophthalmology 1993;100(6):809-17
   PubMed Web of Science ®Google Scholar
• Sobrinho LG, Levine RA, DeConti RC. Amenorrhea in patients with Hodgkin’s disease treated with antineoplastic agents. Am J Obstet Gynecol 1971;109(1):135-9
   PubMedGoogle Scholar
• Berk PD, Goldberg JD, Silverstein MN, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 1981;304(8):441-7
   PubMed Web of Science ®Google Scholar
• Lerner HJ. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 1978;62(8):1135-8
   PubMedGoogle Scholar
• Williams SA, Makker SP, Grupe WE. Seizures: a significant side effect of chlorambucil therapy in children. J Pediatr 1978;93(3):516-18
   PubMedGoogle Scholar
• Lee K, Bajwa A, Freitas-Neto C, et al. A comprehensive review and update on the biologic treatment of adult noninfectious uveitis: part II. Expert Opin Biol Ther 2014;14(11); In press
   Google Scholar